HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy.
cutaneous melanoma
dendritic cells
distant metastasis-free survival
high endothelial venules
metastatic tumor-draining lymph nodes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
07
08
2023
medline:
12
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Tissue biomarkers that aid in identifying cutaneous melanoma (CM) patients who will benefit from adjuvant immunotherapy are of crucial interest. Metastatic tumor-draining lymph nodes (mTDLN) are the first encounter site between the metastatic CM cells and an organized immune structure. Therefore, their study may reveal mechanisms that could influence patients´ outcomes. Twenty-nine stage-III CM patients enrolled in clinical trials to study the vaccine VACCIMEL were included in this retrospective study. After radical mTDLN dissection, patients were treated with VACCIMEL (n=22) or IFNα-2b (n=6), unless rapid progression (n=1). Distant Metastasis-Free Survival (DMFS) was selected as an end-point. Two cohorts of patients were selected: one with a good outcome (GO) (n=17; median DMFS 130.0 months), and another with a bad outcome (BO) (n=12; median DMFS 8.5 months). We analyzed by immunohistochemistry and immunofluorescence the expression of relevant biomarkers to tumor-cell biology and immune cells and structures in mTDLN, both in the tumor and peritumoral areas. In BO patients, highly replicating Ki-67 The analysis of mTDLN in GO and BO patients revealed marked differences. This work highlights the importance of analyzing resected mTDLN from CM patients and suggests a correlation between tumor and immune characteristics that may be associated with a spontaneous or vaccine-induced long DMFS. These results should be confirmed in prospective studies.
Identifiants
pubmed: 37691949
doi: 10.3389/fimmu.2023.1231734
pmc: PMC10485604
doi:
Substances chimiques
Adjuvants, Immunologic
0
Adjuvants, Pharmaceutic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231734Informations de copyright
Copyright © 2023 Bravo, Aris, Panouillot, Porto, Dieu-Nosjean, Teillaud, Barrio and Mordoh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA. 1994 Mar 23-30;271(12):907-13
pubmed: 8120958
Glycobiology. 2010 Sep;20(9):1170-85
pubmed: 20507883
Front Immunol. 2019 Sep 18;10:2213
pubmed: 31620131
Nat Rev Immunol. 2011 Oct 25;11(11):750-61
pubmed: 22025054
Cancer Res. 2011 Dec 1;71(23):7137-40
pubmed: 22131348
Medicina (B Aires). 1997;57(4):421-7
pubmed: 9674264
Nat Biomed Eng. 2021 Dec;5(12):1426-1436
pubmed: 34282290
Cell. 2023 Mar 16;186(6):1127-1143.e18
pubmed: 36931243
Cancer Cell. 2022 Aug 8;40(8):798-799
pubmed: 35839777
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20429-34
pubmed: 19915147
For Immunopathol Dis Therap. 2015;6(1-2):7-17
pubmed: 28286692
PLoS One. 2012;7(7):e40311
pubmed: 22768350
Cancer Immunol Res. 2017 Nov;5(11):1005-1015
pubmed: 28947544
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366174
Nature. 2011 Nov 13;479(7374):542-6
pubmed: 22080953
Genomics. 2005 Apr;85(4):503-11
pubmed: 15780753
Cancer Immunol Res. 2017 Nov;5(11):969-977
pubmed: 28935649
Sci Immunol. 2021 Sep 10;6(63):eabg3551
pubmed: 34516744
Angiogenesis. 2021 Nov;24(4):719-753
pubmed: 33956259
Commun Biol. 2022 Dec 24;5(1):1416
pubmed: 36566320
Immunology. 2021 Sep;164(1):148-160
pubmed: 33934334
Lancet Oncol. 2021 May;22(5):643-654
pubmed: 33857412
Am Soc Clin Oncol Educ Book. 2018 May 23;38:759-762
pubmed: 30231370
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Immunother. 2006 Jul-Aug;29(4):444-54
pubmed: 16799340
Front Immunol. 2015 Mar 30;6:144
pubmed: 25870600
J Cancer. 2019 Jun 2;10(14):3239-3245
pubmed: 31289595
Front Immunol. 2022 Apr 01;13:842555
pubmed: 35432383
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
J Transl Med. 2008 Jan 25;6:6
pubmed: 18221542
PLoS Pathog. 2010 Mar 05;6(3):e1000798
pubmed: 20221423
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
Nature. 2023 Jan;613(7945):743-750
pubmed: 36631610
J Invest Dermatol. 2014 Aug;134(8):2202-2211
pubmed: 24522433
J Clin Oncol. 2023 Jan 20;41(3):425-435
pubmed: 36649675
Clin Cancer Res. 2022 May 13;28(10):2069-2081
pubmed: 35046061
Cancer Immunol Immunother. 2015 Nov;64(11):1393-406
pubmed: 26197849
Nat Immunol. 2022 May;23(5):660-670
pubmed: 35241833
Front Immunol. 2017 May 31;8:625
pubmed: 28620382
J Immunol. 2005 Apr 1;174(7):3920-4
pubmed: 15778347
Lab Invest. 2017 Jan;97(1):4-13
pubmed: 27869795
N Engl J Med. 2020 Sep 17;383(12):1139-1148
pubmed: 32877599
Blood. 2006 Jan 1;107(1):373-80
pubmed: 16189277
Immunity. 1998 Sep;9(3):325-36
pubmed: 9768752
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35074904
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Front Immunol. 2020 Jun 05;11:1147
pubmed: 32582212
Pathol Oncol Res. 2022 Apr 22;28:1610297
pubmed: 35531074
Cell Rep Med. 2022 May 17;3(5):100621
pubmed: 35584631
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6786-6791
pubmed: 29891680
Am J Clin Pathol. 2010 Apr;133(4):646-53
pubmed: 20231618
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Front Immunol. 2021 Jun 30;12:698604
pubmed: 34276690